People

Dulisco Team

Eveline

Eveline Hogenkamp – CEO

Eveline is an experienced Business leader, as former MD of a business unit in the pharma industry, with a solid background in finance and supply chain, with over 13 years of experience in life sciences in both pharma and medical devices. She has a broad experience in mergers, acquisitions and integration. Since 2018 she is fully focused on accelerating the potential of a portfolio of life sciences businesses.

Marty Wulferink – European and Dutch Patent Attorney

Marty is experienced in the field of advising start-up companies, SME’s and universities concerning biological and/or pharmaceutical inventions, diagnostic inventions, licensing, research agreements, Third Party Rights analyses (FTOs), a.o. He drafted several patent applications and was involved in prosecution procedures in most major PCT contracting states. Marty has a strong background in cell biology and immunology and insight in clinical pharmaceutical development.

Marty
Henk

Henk van der Meer – Financial Specialist

Henk is an experienced advisor in the field of finance and control. After being in a financial management role for a life sciences scale-up for over 10 years, Henk is currently supporting and advising young and growing companies regarding all kinds of financial aspects. 

Juul Zwinkels – Marketing and Communications Specialist

Juul is an experienced Marketing and Communications Specialist. Due to her background in Biology and experience in consulting she is able to support pharma companies on topics like proposition and market positioning, branding, PR and content writing for specific target groups. 

Juul
Iris

Iris Garnier – Human Resource Specialist

Iris is an experienced Human Resources Manager in both multinationals and small scaleup companies. She has skills in Talent Management, HR Consulting, HR Solutions and Coaching. She is certified Profile Dynamics Consultant and trained in the Rockefeller Habits methodology.

Board

Jan

Jan van der Hoeven – BIOX Biosciences

Jan is an investor in the field of Life Sciences. He has more than 30 years of operating, scientific and financial experience in private equity backed life sciences companies. He has been involved in a number of successful international merger & acquisition deals. He is a Toxicologist with a very successful track record. He is active in a number of funds to stimulate Life Sciences Companies. 

 

Eveline Hogenkamp – Beukenlaantje

Eveline is an experienced Business leader, as former MD of a business unit in the pharma industry, with a solid background in finance and supply chain, with over 13 years of experience in life sciences in both pharma and medical devices. She has a broad experience in mergers, acquisitions and integration. Since 2018 she is fully focused on accelerating the potential of a portfolio of life sciences businesses.

 

Eveline
Cees

Cees de Wolff – LUPUS Ventures

Cees is co-owner of De Wolff Verenigde Bedrijven. Cees brings 30 years of no-nonsense hands-on business experience and serves as advisor and/or board member in a large number of innovative companies. He has a successful track record in wind power business and merger and acquisition deals. He is active in a number of funds to stimulate Life Sciences Companies.

 

Advisory Board

Wiebe Olijve (PhD)

Wiebe Olijve is an experienced research leader who has developed a range of biotech applications throughout his career. Until recently he was the CEO and co-founder of BioNovion (now Aduro Biotech Europe). Before that, he was vice president of Schering-Plough Biopharma (now Merck Research Laboratories). He also founded the Organon Research Center in Cambridge, Massachusetts, where antibodies against oncological and auto-immune diseases were developed. During this time, Dr Olijve led the project that discovered pembrolizumab (Keytruda) – a humanized antibody used in cancer immunotherapy. He also spent many years leading pioneering research programs at Organon, using genomic and bioinformatics approaches to identify therapeutic targets. These endeavors advanced research in the Netherlands and the United States. Dr Olijve has been a professor of Applied Biology at Radboud University in Nijmegen since 1990.

Bert Pauli

Bert Pauli is a very experienced strategic advisor. During his political career at the Province of Noord-Brabant, he has been the driving force behind creating the conditions needed for enabling companies to accelerate their business. Thanks to his extensive corporate experience and his role in the Province’s economic department, he knows what strategic decisions need to be taken to achieve economic growth and acceleration. Bert Pauli has acted in various management roles and served as a board member in various internationally operating companies, including Ahold, The Greenery and PhotonDelta. After his role as alderman in the department of economic affairs, finance and traffic of the municipality of ‘s-Hertogenbosch, Pauli was a member of the provincial board on economic affairs, in combination with governance and international affairs, for over eight years.

Prof. Dr Herbert (Bob) Pinedo, M.D., Ph.D.,

Prof. Dr. Bob Pinedo retired in 2008 as Professor of Medical Oncology at the Vrije University Medical Center and as Director of the VUmc Cancer Center Amsterdam where he is still acting as a consultant to the board. He was a member of the NCI-EORTC-CRC Committee for Development of New Drugs from 1986 until 1998.

Prof. Dr. Bob Pinedo, is acting as Visiting Professor at the Johns Hopkins University (Baltimore, USA) and Technical University Twente since 2008. He serves as Chairman of the Board of the Caribbean Prevention Center in Curaçao is Chairman of the International Advisory Board of the Vrije University Imaging Center. Professor Pinedo is founder and advisor to Qurin Diagnostics and consultant to a number of start-ups since 2018.

Professor Pinedo is a member of the Royal Dutch Academy of Science and Arts (KNAW), where he was Chairman of the Board of the Medical Division. He has served on the boards of numerous pharmaceutical companies in Europe and United States. He founded the New Drug Development Office – Oncology was past director, member of the administrative board, and consultant (1984-2010) to the Office, which coordinated early clinical trials with anticancer agents internationally. Related to this he established the annual NCI-EORTC symposia on new drugs in Amsterdam and was president of the symposia.

He was the first President of the Federation of European Cancer Societies, (FECS) and European Cancer Organization (ECCO) (1982-1984), and remained member of the Board for ten years (1982-1992).

Pinedo was second President to the European Society of Medical Oncology (ESMO) (1987-1989). During his presidency he took the venue of the meeting from France to allover Europe. He was actively involved in the American Society of Clinical Oncology (ASCO), where he was member of various committees:

  • Program Committee, Subcommittee Clinical Pharmacology (1997-2000)
  • Editorial Board Journal of Clinical Oncology (2002-2006)
  • Cancer Research Committee (2006-2008)
  • International Advisory Committee (2006-2010)
  • International Committee Trials Workshop (ICTW) (2010-2015)

Furthermore, he co-founded the Annals of Oncology and The Oncologist and was the Co-Editor of Current Opinion in Anticancer Drugs. He has served on numerous editorial boards, including those of Clinical Cancer Research and Journal of Clinical Oncology. He has authored more than 650 peer-reviewed international publications (excluding national publications and abstracts) and published more than 120 chapters, invited papers or proceedings. In 2006 the KNAW Bob Pinedo Cancer Care Award was established in his honor, a biennial award for internationally acclaimed researchers in (translational) cancer research and compassionate cancer patient care.

He has received many international awards including the prestigious Josef Steiner award, Spinoza Award, and in 2014 the ASCO David Karnofsky memorial lecture and award. Has been decorated by H.M. Queen Beatrix of the Netherlands with the prestigious Knight of the Order of the Netherlands Lion and Commander in the Order of Orange-Nassau.